JP2021504414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021504414A5 JP2021504414A5 JP2020529467A JP2020529467A JP2021504414A5 JP 2021504414 A5 JP2021504414 A5 JP 2021504414A5 JP 2020529467 A JP2020529467 A JP 2020529467A JP 2020529467 A JP2020529467 A JP 2020529467A JP 2021504414 A5 JP2021504414 A5 JP 2021504414A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- antibody
- antigen
- disorder
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- JOZQZYKBYAUYOK-UHFFFAOYSA-N CC(C)C(CO1)OC1=O Chemical compound CC(C)C(CO1)OC1=O JOZQZYKBYAUYOK-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762592169P | 2017-11-29 | 2017-11-29 | |
| US62/592,169 | 2017-11-29 | ||
| PCT/US2018/063171 WO2019108860A1 (en) | 2017-11-29 | 2018-11-29 | Compositions and methods for the depletion of cd2+ cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021504414A JP2021504414A (ja) | 2021-02-15 |
| JP2021504414A5 true JP2021504414A5 (enExample) | 2022-01-11 |
Family
ID=66664617
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020529467A Pending JP2021504414A (ja) | 2017-11-29 | 2018-11-29 | Ｃｄ２＋細胞の枯渇のための組成物および方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200368363A1 (enExample) |
| EP (1) | EP3717519A4 (enExample) |
| JP (1) | JP2021504414A (enExample) |
| KR (1) | KR20200090801A (enExample) |
| CN (1) | CN111670200A (enExample) |
| AU (1) | AU2018374282A1 (enExample) |
| BR (1) | BR112020010816A2 (enExample) |
| CA (1) | CA3082166A1 (enExample) |
| CO (1) | CO2020006855A2 (enExample) |
| EA (1) | EA202090922A1 (enExample) |
| IL (1) | IL274817A (enExample) |
| MX (1) | MX2020004806A (enExample) |
| SG (1) | SG11202004192XA (enExample) |
| WO (1) | WO2019108860A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3107378A1 (en) * | 2018-07-23 | 2020-01-30 | Magenta Therapeutics, Inc. | Use of an anti-cd2 antibody drug conjugate (adc) in allogeneic cell therapy |
| US20230365687A1 (en) * | 2020-06-23 | 2023-11-16 | Zelarion Malta Limited | Anti-cd2 antibodies |
| US20240216336A1 (en) * | 2020-07-28 | 2024-07-04 | Northwestern University | Clotrimazole as a treatment for immunodeficiency disorders |
| WO2023224980A1 (en) * | 2022-05-17 | 2023-11-23 | The Uab Research Foundation | Methods and compositions for treating or preventing inflammatory skin disorders |
| WO2024079046A1 (en) * | 2022-10-10 | 2024-04-18 | Zelarion Malta Limited | Anti-cd2 antibodies for type 1 diabetes |
| EP4626926A2 (en) * | 2022-11-28 | 2025-10-08 | iCell Gene Therapeutics Inc. | Engineered immune cells for treating disorders, compositions and methods thereof |
| TW202535955A (zh) * | 2023-11-27 | 2025-09-16 | 丹麥商珍美寶股份有限公司 | 用於ｐｔｋ７檢測之抗體及方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7592006B1 (en) * | 1993-03-05 | 2009-09-22 | Université Catholique de Louvain | Composition comprising the LO-CD2a antibody |
| ES2164699T3 (es) * | 1993-03-05 | 2002-03-01 | Univ Catholique Louvain | Anticuerpo lo-cd2a y usos del mismo para inhibir la activacion y la proliferacion de las celulas t. |
| US5795572A (en) * | 1993-05-25 | 1998-08-18 | Bristol-Myers Squibb Company | Monoclonal antibodies and FV specific for CD2 antigen |
| JP4808841B2 (ja) * | 1997-07-18 | 2011-11-02 | バイオトランスプラント，インコーポレイテッド | Ｔ細胞活性化および増殖を阻害するＬＯ−ＣＤ２ａ抗体およびその使用法 |
| US6849258B1 (en) * | 1997-07-18 | 2005-02-01 | Universite Catholique De Louvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
| JP2001523645A (ja) * | 1997-11-14 | 2001-11-27 | ザ・ゼネラル・ホスピタル・コーポレイション | 血液学的疾患の処置 |
| JP4741838B2 (ja) * | 2002-07-31 | 2011-08-10 | シアトル ジェネティクス，インコーポレーテッド | 癌、自己免疫疾患または感染症を治療するための薬物結合体およびその使用 |
| US20040265315A1 (en) * | 2002-09-05 | 2004-12-30 | Christine Dingivan | Methods of preventing or treating T cell malignancies by administering CD2 antagonists |
| CN105377304B (zh) * | 2014-03-10 | 2018-05-15 | 海德堡医药有限责任公司 | 鹅膏毒肽衍生物 |
| SG11201703446RA (en) * | 2014-10-31 | 2017-05-30 | Abbvie Biotherapeutics Inc | Anti-cs1 antibodies and antibody drug conjugates |
| CN107921144B (zh) * | 2015-06-20 | 2023-11-28 | 杭州多禧生物科技有限公司 | 澳瑞他汀类似物及其与细胞结合分子的共轭偶联物 |
| JP2022530026A (ja) * | 2019-04-24 | 2022-06-27 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アマトキシン抗体薬物複合体及びその使用 |
-
2018
- 2018-11-29 JP JP2020529467A patent/JP2021504414A/ja active Pending
- 2018-11-29 CA CA3082166A patent/CA3082166A1/en active Pending
- 2018-11-29 EA EA202090922A patent/EA202090922A1/ru unknown
- 2018-11-29 CN CN201880088127.XA patent/CN111670200A/zh active Pending
- 2018-11-29 SG SG11202004192XA patent/SG11202004192XA/en unknown
- 2018-11-29 MX MX2020004806A patent/MX2020004806A/es unknown
- 2018-11-29 US US16/768,036 patent/US20200368363A1/en not_active Abandoned
- 2018-11-29 KR KR1020207016423A patent/KR20200090801A/ko not_active Ceased
- 2018-11-29 EP EP18883544.1A patent/EP3717519A4/en not_active Withdrawn
- 2018-11-29 AU AU2018374282A patent/AU2018374282A1/en not_active Abandoned
- 2018-11-29 WO PCT/US2018/063171 patent/WO2019108860A1/en not_active Ceased
- 2018-11-29 BR BR112020010816-2A patent/BR112020010816A2/pt not_active IP Right Cessation
-
2020
- 2020-05-20 IL IL274817A patent/IL274817A/en unknown
- 2020-06-03 CO CONC2020/0006855A patent/CO2020006855A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021504414A5 (enExample) | ||
| JP2019522050A5 (enExample) | ||
| WO2019108863A4 (en) | Compositions and methods for the depletion of cd5+ cells | |
| DK1507556T3 (en) | Calicheamicin derivative-carrier conjugates | |
| WO2019108860A4 (en) | Compositions and methods for the depletion of cd2+ cells | |
| DiJoseph et al. | Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22 | |
| JP2021500391A5 (enExample) | ||
| RU2008149918A (ru) | Антитела к nkg2a и их применения | |
| US20240226318A1 (en) | Antibody drug conjugate targeting nectin 4 and preparation method therefor and use thereof | |
| JP7785284B2 (ja) | Ｃｄ３８抗体とｉｃａｍ１抗体およびそれらの使用 | |
| RU2012142311A (ru) | Интерлейкин-13-связывающие белки | |
| WO2018210795A1 (en) | ANTI-SIRPα ANTIBODIES | |
| RU2018130757A (ru) | Конъюгаты антитела к cd74, композиции, содержащие конъюгаты антитела к cd74, и способы использования конъюгатов антитела к cd74 | |
| CA2153692A1 (en) | Recombinant anti-vla4 antibody molecules | |
| RU2010133892A (ru) | Гуманизированные моноклональные антитела против человеческого nkg2a | |
| HRP20240939T1 (hr) | Anti-cd3 protutijela i metode uporabe | |
| RU2019140602A (ru) | АНТИ-GARP-TGF-β-АНТИТЕЛА | |
| JP2006506955A5 (enExample) | ||
| RU2009136913A (ru) | Биспецифические связывающие агенты с межвидовой специфичностью | |
| JP2016503067A5 (enExample) | ||
| WO2013072523A4 (en) | Bi-specific antibodies for medical use | |
| IL305954A (en) | Nectin-4 protein antibody and extacan compounds | |
| CN111886023A (zh) | 针对tim-3的抗体及其用途 | |
| WO2022268050A1 (zh) | 一种药物组合及其用途 | |
| JPWO2019246110A5 (enExample) |